Celiac.com 07/29/2021 - Ukko, a company focused on developing artificial-intelligence designed products and solutions to food allergies, just announced a successful $40 million funding round.
Their first effort will be to develop non-allergenic gluten protein and gluten-neutralized ingredients that can be used to in baked goods for celiacs and people with gluten sensitivity.
Celiac.com Sponsor (A12):
At the same time, they are also working on a safe peanut allergy treatment that focuses on creating a safer therapeutic approach for allergic people undergoing desensitization treatment. Ukko plans to develop a safer peanut allergy treatment by using their non-allergenic version of peanut protein.
For gluten allergies, Ukko is working on a safe gluten protein that can be used for numerous products in both commercial and manufacturing markets. Interestingly, Ukko also plans to use its flour products to produce their own line of gluten-free bread that will be available commercially.
Current investors in Ukko include lead investor Leaps by Bayer, the venture arm of the pharmaceutical giant, Continental Grain Company, PeakBridge Ventures, SkyViews Life Science and Fall Line Capital, Khosla Ventures, Innovation Endeavors, and TIME Ventures.
Read more in Food Dive.
Recommended Comments
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now